Bain Capital Life Sciences Investors’s Dynavax Technologies DVAX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio DVAX Stock Details DVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-915,000	Closed	-$13.5M	–	29
2023 Q3	$13.5M	Sell	915,000 -1,500,000	-62%	-$21.1M	1.51%	17
2023 Q2	$31.2M	Sell	2,415,000 -1,500,000	-38%	-$17.1M	3.21%	10
2023 Q1	$38.4M	Hold	3,915,000	–	–	4.8%	6
2022 Q4	$41.7M	Sell	3,915,000 -1,500,000	-28%	-$17.4M	4.66%	8
2022 Q3	$56.5M	Sell	5,415,000 -3,000,000	-36%	-$39.1M	6.75%	5
2022 Q2	$106M	Hold	8,415,000	–	–	12.42%	2
2022 Q1	$91.2M	Hold	8,415,000	–	–	8.86%	2
2021 Q4	$118M	Hold	8,415,000	–	–	9.39%	2
2021 Q3	$162M	Sell	8,415,000 -3,356,708	-29%	-$44.6M	10.03%	2
2021 Q2	$116M	Buy	11,771,708 +875,935	+8%	+$7.96M	7.6%	3
2021 Q1	$107M	Hold	10,895,773	–	–	6.07%	4
2020 Q4	$48.5M	Hold	10,895,773	–	–	3.04%	10
2020 Q3	$47.1M	Hold	10,895,773	–	–	4.39%	7
2020 Q2	$96.6M	Buy	10,895,773 +2,165,066	+25%	+$10.9M	10.12%	4
2020 Q1	$30.8M	Buy	8,730,707 +278,472	+3%	+$1.29M	5.21%	5
2019 Q4	$48.3M	Hold	8,452,235	–	–	7.21%	4
2019 Q3	$30.3M	Buy	+8,452,235	New	+$32.8M	7.79%	5

Other funds holding DVAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bain Capital Life Sciences Investors's DVAX Position: Q4 2023 in Review

Bain Capital Life Sciences Investors sold out of Dynavax Technologies (DVAX) in Q4 2023, closing a stake of 915,000 shares — an estimated $13.5M sold.

Bain Capital Life Sciences Investors first reported a position in DVAX in Q3 2019 and held it in 17 quarters. The position peaked at $162M in Q3 2021. 246 funds tracked by Wall St. Rank hold DVAX as of Q4 2023.

Bain Capital Life Sciences Investors reported no remaining Dynavax Technologies position as of Q4 2023 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 915,000 Dynavax Technologies shares in Q4 2023, an estimated $13.5M.
Bain Capital Life Sciences Investors first reported a position in Dynavax Technologies in Q3 2019 and held it in 17 quarters.
Bain Capital Life Sciences Investors's Dynavax Technologies position peaked at $162M in Q3 2021.
246 funds tracked by Wall St. Rank held Dynavax Technologies as of Q4 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2023, filed 13 Feb 2024.